Respiratory researchers in the UK are launching a trial to test a novel treatment for inflammatory lung conditions in hospitalised Covid-19 patients. Brensocatib, a reversible inhibitor of dipeptidyl peptidase 1 (DPP1) currently being developed by biopharmaceutical company Insmed, will be tested in 300 patients across 10 UK sites after recent positive results in in adult ...
STOP-COVID19 trial to test novel bronchiectasis treatment
By Emma Wilkinson
27 Apr 2020